Evaluation of the safety of a strategy combining etanercept administration with repeated contrast ultrasound in patients with Alzheimer's disease: a phase I study

2023-505714-19-00 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 16 Apr 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 5
Countries 1
Sites 1

Alzheimer's disease

Key facts

Sponsor
Hopital Fondation Adolphe De Rothschild
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
16 Apr 2025 → ongoing
Decision date (initial)
2024-07-01
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Alzheimer's disease

VersionLevelCodeTermSystem organ class
20.0 LLT 10001896 Alzheimer's disease 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Hopital Fondation Adolphe De Rothschild

Sponsor organisation
Hopital Fondation Adolphe De Rothschild
Address
25 Rue Manin
City
Paris
Postcode
75019
Country
France

Scientific contact point

Organisation
Hopital Fondation Adolphe De Rothschild
Contact name
Amélie Yavchitz

Public contact point

Organisation
Hopital Fondation Adolphe De Rothschild
Contact name
Amélie Yavchitz

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 5 1
Rest of world 0

Investigational sites

France

1 site · Ongoing, recruiting
Hopital Fondation Adolphe De Rothschild
Neuroradiologue, 25 Rue Manin, 75019, Paris

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-04-16 2026-03-17

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-03-11 France Acceptable
2024-07-01
2024-07-01
2 SUBSTANTIAL MODIFICATION SM-1 2025-01-29 France Acceptable
2025-03-28
2025-03-28
3 SUBSTANTIAL MODIFICATION SM-2 2025-06-20 France Acceptable
2025-08-01
2025-08-01
4 SUBSTANTIAL MODIFICATION SM-3 2026-04-09 France Acceptable
2026-05-11
2026-05-21